The progressive elevation of NT-proBNP during chemotherapy is related to asymptomatic cardiovascular events in patients with multiple myeloma
Multiple myeloma (MM) is a malignant monoclonal plasma cell disorder that accounts for 10% of all hematological malignancies.1, 2 The survival of patients with MM has improved significantly in the last decade due to a combination of immunomodulatory agents, corticosteroids, and proteasome inhibitors.3, 4 Meanwhile, multidrug therapy and long-term treatment have raised the incidence of treatment-related cardiovascular events (CVEs). CVEs are increasingly relevant to prognosis and even contribute to early mortality in patients with MM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Yutong Wang, Li Bao, Bin Chu, Shan Gao, Minqiu Lu, Lei Shi, Lina Fu, Lijuan Fang, Qiuqing Xiang Source Type: research
More News: Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | Corticosteroid Therapy | Heart | Hematology | Leukemia | Lymphoma | Myeloma